Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis

@article{Lattanzi2020CannabidiolEA,
  title={Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis},
  author={Simona Lattanzi and Eugen Trinka and Pasquale Striano and Gaetano Zaccara and Cinzia Del Giovane and Raffaele Nardone and Mauro Silvestrini and Francesco Brigo},
  journal={Epilepsia},
  year={2020},
  volume={61},
  pages={1090 - 1098}
}
To evaluate the potential impact of concomitant clobazam (CLB) use on the efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome and Lennox‐Gastaut syndrome using meta‐analytical techniques. 

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox‐Gastaut syndrome, and two

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials

To assess the efficacy and safety profile of add‐on cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of four

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), post hoc analyses of data from two randomized, placebo‐controlled, Phase 3 trials of patients with Lennox–Gastaut syndrome were conducted.

Cannabidiol efficacy and clobazam coadministration: Where do we stand now?

The paradoxical increases in seizure frequency observed in a subset of CLBOff patients with Lennox-Gastaut syndrome attenuated the response in change in the seizure count analysis, without affecting or having little impact on the ≥50% responder rate.

Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials

The best clinical evidence to date is provided that CBD exerts therapeutic effects in patients with epilepsy that are independent of its interaction with CLB, and greater antiseizure effects, and a greater burden of adverse effects, are observed when CBD is combined withCLB.

Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps

The most striking gaps in knowledge are the efficacy and optimal dose of CBD for adults with focal epilepsies, the long-term safety of CBD use, and strategies to improve access to CBD for people living with epilepsy.

Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

Cannabidiol is slightly inferior to the other three antiseizure medications in terms of efficacy and safety, but soticlestat and fenfluramine are safer.

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

This review will critically review the pharmacokinetic properties of CBD, the interactions with antiseizur and non-antiseizure medications, and the main tolerability and safety issues to provide guidance for its use in everyday practice.

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

CBD is associated with improved seizure control also in a considerable proportion of highly refractory patients with DS and LGS independently from clobazam use, and overall, CBD safety and effectiveness are not dose-related in this cohort.

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

The CBMF is a highly effective and safety therapy to treat adult patients with DRFE, and the reduction in seizures frequency is maintained over time.

References

SHOWING 1-10 OF 33 REFERENCES

Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

This randomized clinical trial evaluates the efficacy and safety of 2 doses of a pharmaceutical formulation of cannabidiol vs placebo for adjunctive treatment of convulsive seizures in patients with

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

The present study aimed to address the nature of the interaction between CBD and clobazam to address speculation that the anticonvulsant efficacy of CBD may simply reflect CBD augmenting clobzam exposure.

Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis

Adjunctive CBD resulted in a greater reduction in seizure frequency and a higher rate of AEs than placebo in patients with LGS presenting seizures uncontrolled by concomitant AEDs.

Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety

Adjunctive CBD resulted in a greater reduction in convulsive seizure frequency than placebo and a higher rate of AEs in patients with DS presenting with seizures uncontrolled by concomitant antiepileptic therapy.

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

The aim of the study was to estimate the efficacy and safety of CBD as adjunctive treatment in patients with epilepsy using meta-analytical techniques.

Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

A critical review of the pharmacology of CBD and the most recent clinical studies that evaluated its efficacy and safety as adjunctive treatment of seizures associated with LGS and DS are provided.

Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex

CBD, a nonpsychoactive compound derived from the marijuana plant, is evaluated as an adjunct to current antiepileptic drugs in patients with refractory seizures in the setting of TSC.

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

Among children and adults with the Lennox–Gastaut syndrome, the addition of cannabidiol at a dose of 10 mg or 20 mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo.

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety

Erenumab is an efficacious and well tolerated preventive treatment in adult patients with episodic and chronic migraine and there were no differences in the occurrence of AEs, SAEs, and drug withdrawal due to AEs between the erenumAB and placebo groups.